Bretylium
 | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | IV, IM |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | NA |
| Metabolism | None |
| Elimination half-life | 7-8 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C11H17BrN+ |
| Molar mass | 243.163 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Bretylium (also bretylium tosylate) blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, & other specialties for the acute management of ventricular tachycardia & ventricular fibrillation. It is contraindicated in patients with AV (atrioventricular) heart block or digoxin toxicity.
Bretylium is only used in an ICU setting and should not be used elsewhere due to its dramatic actions and its predominant side effect of hypotension.